Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of SymBio Pharmaceuticals Limited. A complete text table follows the diagram.
The filing reports a substantial loss-making cost base with no operating revenue fact.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Reported selling and administrative expenses | 1 | 2.6B | 100.0% of reported total |
| Biotech development operating costs | 2 | 2.6B | Reported six-month total · ¥2.6B |
| Operating loss | 2 | 2.2B | Absolute value of reported operating loss |
| Operating costs & expenses | 3 | 4.8B | Revenue plus reported operating loss |
| From | To | Value |
|---|---|---|
| Reported selling and administrative expenses | Biotech development operating costs | 2.6B |
| Biotech development operating costs | Operating costs & expenses | 2.6B |
| Operating loss | Operating costs & expenses | 2.2B |